"Vaccination with HPV16 Peptides of Patients with Advanced Cervical Carcinoma: Clinical Evaluation of a Phase I-II Trial."

According to the authors' abstract of an article published in European Journal of Cancer, "A Phase I-II clinical trial was performed involving vaccination with HPV16 E7 peptides of patients suffering from HPV16 positive cervical carcinoma which was refractory to conventional treatment. Patients receiving the vaccine were HLA-A(star)0201 positive with HPV16 positive cervical carcinoma. The clinical trial was designed as a dose-escalation study, in which successive groups of patients received 100 (mu)g, 300 (mu)g, or 1,000 (mu)g of each peptide, respectively. The vaccine consisted of two HPV16 E7 peptides and one helper peptide emulsified in Montanide ISA 51 adjuvant. Nineteen patients...

Want to see the full article?

• Purchase this article for only $3.00